Cassava Sciences reports Q3 net loss $27.9M; RETHINK-ALZ top-line data expected by end-2024

FILANA THERAPEUTICS, INC.

Net loss $27.9M ($0.58 per share) vs $25.7M ($0.61) in Q3 2023; cash $149M at Sep 30, 2024.
Top-line results from Phase 3 RETHINK-ALZ trial (simufilam) expected before end of 2024.
DSMB recommended both Phase 3 studies continue as planned at Sep 2024 meeting.
Year-end 2024 cash estimated $117-127M; $40M SEC settlement in escrow excluded.
Open-label extension study enrolled over 1,040 patients; 88% opt-in rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.